Literature DB >> 17393954

Hepatosteatosis with hypobetalipoproteinemia.

Didem Sen1, Selcuk Dagdelen, Tomris Erbas.   

Abstract

Nonalcoholic fatty liver disease is increasingly recognized as a condition that may progress to chronic liver disease. Most cases of fatty liver are asymptomatic and often are detected during routine medical or laboratory examinations. There also are some rare genetic diseases such as abetalipoproteinemia and familial hypobetalipoproteinemia that may cause fatty liver disease. Both are inherited disorders of lipoprotein metabolism. Although abetalipoproteinemia and homozygous familial hypobetalipoproteinemia patients present with severe manifestations, heterozygotes are usually asymptomatic. In the last several years, case reports or studies indicating a relationship between hepatosteatosis and familial heterozygote hypobetalipoproteinemia (FHBL) have been reported. Here, we report three cases of FHBL with characteristic lipid profile, mildly elevated liver enzymes and hepatosteatosis confirmed by ultrasonography.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17393954      PMCID: PMC2569618     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  8 in total

Review 1.  Nonalcoholic fatty liver disease.

Authors:  Paul Angulo
Journal:  N Engl J Med       Date:  2002-04-18       Impact factor: 91.245

2.  Asymptomatic elevation of aminotransferase levels and fatty liver secondary to heterozygous hypobetalipoproteinemia.

Authors:  A Ahmed; E B Keeffe
Journal:  Am J Gastroenterol       Date:  1998-12       Impact factor: 10.864

3.  Understanding the pathophysiology of dysphagia and constipation in neurologic disorders.

Authors:  A Wald
Journal:  Am J Gastroenterol       Date:  1994-01       Impact factor: 10.864

Review 4.  Clinical features and natural history of nonalcoholic steatosis syndromes.

Authors:  Y Falck-Ytter; Z M Younossi; G Marchesini; A J McCullough
Journal:  Semin Liver Dis       Date:  2001       Impact factor: 6.115

5.  A targeted apolipoprotein B-38.9-producing mutation causes fatty livers in mice due to the reduced ability of apolipoprotein B-38.9 to transport triglycerides.

Authors:  Z Chen; R L Fitzgerald; M R Averna; G Schonfeld
Journal:  J Biol Chem       Date:  2000-10-20       Impact factor: 5.157

6.  Fatty liver in heterozygous hypobetalipoproteinemia caused by a novel truncated form of apolipoprotein B.

Authors:  P Tarugi; A Lonardo; G Ballarini; A Grisendi; M Pulvirenti; A Bagni; S Calandra
Journal:  Gastroenterology       Date:  1996-10       Impact factor: 22.682

7.  A study of fatty liver disease and plasma lipoproteins in a kindred with familial hypobetalipoproteinemia due to a novel truncated form of apolipoprotein B (APO B-54.5).

Authors:  P Tarugi; A Lonardo; G Ballarini; L Erspamer; E Tondelli; S Bertolini; S Calandra
Journal:  J Hepatol       Date:  2000-09       Impact factor: 25.083

8.  Phenotypic expression of familial hypobetalipoproteinemia in three kindreds with mutations of apolipoprotein B gene.

Authors:  P Tarugi; A Lonardo; C Gabelli; F Sala; G Ballarini; I Cortella; L Previato; S Bertolini; R Cordera; S Calandra
Journal:  J Lipid Res       Date:  2001-10       Impact factor: 5.922

  8 in total
  4 in total

1.  Clinical utility of genomic analysis in adults with idiopathic liver disease.

Authors:  Aaron Hakim; Xuchen Zhang; Angela DeLisle; Elif A Oral; Daniel Dykas; Kaela Drzewiecki; David N Assis; Marina Silveira; Jennifer Batisti; Dhanpat Jain; Allen Bale; Pramod K Mistry; Silvia Vilarinho
Journal:  J Hepatol       Date:  2019-04-15       Impact factor: 25.083

Review 2.  PNPLA3 genetic variation in alcoholic steatosis and liver disease progression.

Authors:  Felix Stickel; Jochen Hampe; Eric Trépo; Christian Datz; Stefano Romeo
Journal:  Hepatobiliary Surg Nutr       Date:  2015-06       Impact factor: 7.293

Review 3.  Emerging Role of Genomic Analysis in Clinical Evaluation of Lean Individuals With NAFLD.

Authors:  Sílvia Vilarinho; Veeral Ajmera; Melanie Zheng; Rohit Loomba
Journal:  Hepatology       Date:  2021-10       Impact factor: 17.298

Review 4.  Role of mitochondria in nonalcoholic fatty liver disease.

Authors:  Fatiha Nassir; Jamal A Ibdah
Journal:  Int J Mol Sci       Date:  2014-05-15       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.